GovChime
Notice ID: 8784cb2adac44f98a9e818bacc3d6e6eAward NoticeAwarded

Q301--Germline Genetic Lab Testing Services_VHA_National Oncology Program

Awarded on September 27, 2022. Full description on SAM.gov.

Awarded tounder 36C10X22P0119 (source: SAM.gov award notice)• $6.2M

Overview

Posted
September 28, 2022
Notice type
Award Notice

Notice details

Place of performance
See PWS
Last updated
Sep 9, 2025
Award date
Sep 27, 2022
Award amount (SAM.gov award notice)
$6.2M

Identifiers

Solicitation number
36C10X22Q0164
Notice ID
8784cb2adac44f98a9e818bacc3d6e6e
Award number (PIID)
36C10X22P0119

Description

No. Question/Statement Solicitation Reference Answer/Comments 1 Is RNA sequencing a requirement? 36C10X22Q0164 RNA sequencing is preferred but not required. 2 It's mentioned that the contractor should, "Analyze samples and report within a turn-around time of ~2 weeks." The majority of our test are completed within 18 calendar days on average (some may be longer, e.g.: WES and WGS turnaround times are 28 calendar days on average). Is that acceptable? 36C10X22Q0164 ~ 2 weeks is the expectation for small panels and 18 calendar days would fall within that rough estimate. That said, VA's preference is as short of a turnaround time as possible for return of results. It is understandable that WES or WGS may be longer than 2 weeks. In the proposal, please specify if the laboratory can provide some test results more urgently than the 18 day turnaround and if so, would there be an additional cost associated with expedited sample processing. 3 It's mentioned that the contractor should, "Offer ordering provider created custom gene panels (ability to add/subtract genes from already curated panels) at no additional cost." Addition of genes to a panel and pricing will depend largely on the number of genes added and the difficulty involved with analyzing those genes. Often times, adding genes may not affect pricing, but there are cases in which it may. Is that acceptable? 36C10X22Q0164 Please provide examples of when adding genes to a curated panel will be feasible at no additional cost and when it will come with an added cost in the proposal. It is understandable that large additions to a custom gene panel could incur additional cost however addition or subtraction of a few genes from a panel should not incur a charge. VA will need to better understand the situations where these changes to a panel's number of genes trigger an additional charge. 4 Is it okay if a limited number of genes from the PWS Germline pricing schedule are not included? 36C10X22Q0164 It is preferred that all genes on the gene list are included. The proposal should include a comparison of vendor gene panel lists to the VA's list and highlight any differences. VA will use this information to evaluate the significance of the missing lists in our evaluation. 5 If not, is there a quality threshold on what percentage need to be included? 36C10X22Q0164 No. 6 Would a phlebotomy service be used rarely or frequently? 36C10X22Q0164 We estimate that about 15% of all test requests might benefit from a mobile phlebotomy service. 7 How often would the contractor be expected to deliver specimen kits to patient homes? 36C10X22Q0164 About 50% of orders would involve shipment of specimen kits to patient homes 8 Is it descualifying for a laboratory focused on Oncology genetic testing, not to offer the total of mandaroty tests? Specifically those that are not related to Oncology. 36C10X22Q0164 It is a mandatory requirement that test offerings span oncology and other disease areas listed in the Performance Work Statement. Oncology only test offerings would not fulfill this requirement. 9 Being this an Oncology focused program. Is it possible to remove the limitation to process samples no related to Oncology testing by an associated laboratory (not fully owned subsidiaries) and reported by the contractor ? 36C10X22Q0164 It is a mandatory requirement that test offerings span oncology and all other disease areas listed in the Performance Work Statement. 10 What percent of overlap is expected between the list genes for each example and our panels? 36C10X22Q0164 It is preferred that all genes on the gene list are included. The proposal should include a comparison of vendor gene panel lists to the VA's list and highlight any differences. VA will use this information to evaluate the significance of the missing lists in our evaluation. There is no specified overlap requirement outlined in the Performance Work Statement. 11 Is it expected that the contractor ships kits in bulk to the different VA centers or is expected that the contractor ships individual kits to patients homes on request? 36C10X22Q0164 Both are expected. The vendor will need to ship to VA facilities kits used for blood, saliva and/or buccal swab collection. The vendor will need to ship kits for saliva and/or buccal swab collection to patients' homes as well. 12 Since we are running DNA testing, the patient signature is needed, would the provider's attestation be covering the patient consent? 36C10X22Q0164 Patient signature will not typically be obtained on lab requitision form. Obtaining and documenting informed consent is a VA best practice. As such, ordering clinciians will be attesting to the patients' consent for testing. 13 When is the estimated starting date for this contract? 36C10X22Q0164 30-Sep-22 14 Is there an incumbent contractor for this solicitation? 36C10X22Q0164 No

Full description on SAM.gov

Award Overview

Award Number

36C10X22P0119

Award Amount (SAM.gov award notice)

$6.2M

Award Date

Sep 27, 2022

Awardee

Awardee UEI

JVZDRESJLD82

Original Solicitation

Notice ID: 8784cb2adac44f98a9e818bacc3d6e6e

Posted Date: Sep 28, 2022

Original Response Deadline: Not specified

More From This Vendor

Top 5 most recent

5
  • 36C25625C0001
    FULGENT THERAPEUTICS LLC
    Department of Veterans AffairsNAICS 621511
    $567.5KSigned Oct 6, 2026
  • 36C10X26N0165
    FULGENT THERAPEUTICS LLC
    Department of Veterans AffairsNAICS 621511
    $6.6KSigned Sep 21, 2026
  • 36C25625C0001
    FULGENT THERAPEUTICS LLC
    Department of Veterans AffairsNAICS 621511
    $383.8KSigned Sep 2, 2026
  • 36C10X24D0028
    FULGENT THERAPEUTICS LLC
    Department of Veterans AffairsNAICS 621511
    —Signed Jul 3, 2026
  • 36C25625C0001
    FULGENT THERAPEUTICS LLC
    Department of Veterans AffairsNAICS 621511
    $383.8KSigned Jun 5, 2026

Contacts

Documents

No documents available.

Lifecycle

Solicitation:36C10X22Q0164
  1. Market Research
  2. Combined Synopsis
  3. Awarded

This opportunity has been awarded.

  1. Market ResearchMay 26, 2022

    Q301--Germline Genetic Lab Testing Services_VHA_National Oncology Program

    Notice 94a7e2d705534fd99c4d3d815934c9a2 on SAM.gov

  2. 3×
    Combined SynopsisAug 1, 2022

    Q301--Germline Genetic Lab Testing Services_VHA_National Oncology Program Amendment 0001 - Post Answers to Vendor Questions

    Notice 367ec4c9da114269b1002493ed918f91 on SAM.gov

  3. AwardedCurrentSep 28, 2022

    Q301--Germline Genetic Lab Testing Services_VHA_National Oncology Program

    Notice 8784cb2adac44f98a9e818bacc3d6e6e on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

36C10X22Q0164

Archive Date

Nov 27, 2022

Office Address

FREDERICK, MD, 21703